Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162088 | PMC |
| http://dx.doi.org/10.7189/jogh.08.020306 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
NTHi killing activity is reduced in COPD patients and is associated with a differential microbiome.
Respir Res
January 2025
Microbial Antibodies and Technologies, Research and Early Development, Vaccines and Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Chronic obstructive pulmonary disease (COPD) is a chronic lung disease characterized by airway obstruction and inflammation. Non-typeable Haemophilus influenzae (NTHi) lung infections are common in COPD, promoting frequent exacerbations and accelerated lung function decline. The relationship with immune responses and NTHi are poorly understood.
View Article and Find Full Text PDFRisk trajectory of cardiovascular events after an exacerbation of chronic obstructive pulmonary disease: A systematic review and meta-analysis.
Eur J Intern Med
January 2025
Internal Medicine and Stroke Care ward, Department of Promoting Health, Maternal-Infant. Excellence and Internal and Specialized Medicine (Promise) G. D'Alessandro, University of Palermo, Palermo Italy.
Background: Exacerbations of chronic obstructive pulmonary disease (COPD) are known to increase the risk of cardiovascular (CV) events and mortality. However, the temporal trend of this risk has not fully elucidated. This systematic review and meta-analysis aims to quantify the risk of CV events after COPD exacerbations over different time periods.
View Article and Find Full Text PDFPharmacokinetics and absorption, distribution, metabolism and excretion profiling of tanimilast following an intravenous C-microtracer coadministered with an inhaled dose in healthy male individuals.
Drug Metab Dispos
January 2025
Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Tanimilast is an inhaled phosphodiesterase-4 inhibitor currently in phase III clinical development for treating chronic obstructive pulmonary disease and asthma. This trial aimed to characterize the pharmacokinetics, mass balance, and metabolite profiling of tanimilast. Eight healthy male volunteers received a single dose of nonradiolabeled tanimilast via powder inhaler (Chiesi NEXThaler [3200 μg]), followed by a concomitant intravenous infusion of a microtracer ([C]-tanimilast: 18.
View Article and Find Full Text PDFRisk of long covid in patients with pre-existing chronic respiratory diseases: a systematic review and meta-analysis.
BMJ Open Respir Res
January 2025
Department of Medicine, The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, USA
Background: An estimated 10-30% of people with COVID-19 experience debilitating long-term symptoms or long covid. Underlying health conditions associated with chronic inflammation may increase the risk of long covid.
Methods: We conducted a systematic review and meta-analysis to examine whether long covid risk was altered by pre-existing asthma or chronic obstructive pulmonary disease (COPD) in adults.
Preliminary test a two stage, self-determination theory (SDT) and participation-based physical activity and peer support intervention for individuals with Chronic Obstructive Pulmonary Disease (COPD). In Stage 1, four focus groups were conducted to provide insights about individuals' needs and experiences with physical activity. In Stage 2, four individuals with COPD aged 76-90 years (50% female) participated in an eight-week online physical activity and peer support intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!